Clinical Trials Logo
  1. Home
  2. Carcinoma, Squamous Cell
  3. NCT00563927
  4. Details
NCT00563927 Clinical Trial

Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)

Carcinoma, Squamous Cell Clinical Trial

Official title:
Prospective Randomized Study on Therapeutic Gain Achieved By Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT00563927
Other study ID # L/M-77 TO PYH08/79
Secondary ID HARECCTR0500023N
Status Active, not recruiting
Phase N/A
First received November 21, 2007
Last updated July 6, 2010
Start date March 1999
Est. completion date October 2009

Study information
Verified date July 2010
Source Hospital Authority, Hong Kong
Contact n/a
Is FDA regulated No
Health authority Hong Kong: Ethics Committee
Study type Interventional

Clinical Trial Summary

To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 340
Est. completion date October 2009
Est. primary completion date
Accepts healthy volunteers
Gender Both
Age group N/A to 70 Years
Eligibility Inclusion Criteria:

- Undifferentiated or non-keratinizing carcinoma

- Tumor staged as N2-3

- No evidence of distant metastasis M0

- Performance status:0-2

- Marrow: WBC >= 4 and platelet >= 100

- Renal: creatinine clearance >= 60

- Informed consent

Exclusion Criteria:

- WHO type I squamous cell carcinoma or adenocarcinoma

- Age >= 70

- Palliative intent or tumor extent mandating AP opposing facio-cervical fields

- Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years

- Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume

- Previous chemotherapy

- Patient is pregnant or lactating

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Procedure:
• Conventional RT

Drug:
• Cisplatin

• 5-fluorouracil

Locations
Country Name City State
China Pamela Youde Nethersole Eastern Hospital Hong Kong
China Queen Elizabeth Hospital Hong Kong
China Queen Mary Hospital Hong Kong
China Tuen Mun Hospital Hong Kong

Sponsors (2)
Lead Sponsor Collaborator
Hospital Authority, Hong Kong Hong Kong Nasopharyngeal Cancer Study Group Limited

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Failure free survival rate 5 year
Secondary Disease-specific survival rate 5-year
Secondary Overall survival rate 5-year
Secondary Complication-free rates 5-year
See also
  Status Clinical Trial Phase
Recruiting NCT02743832 - A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma. N/A
Active, not recruiting NCT02229656 - Olaparib and Radiotherapy in Head and Neck Cancer Phase 1
Completed NCT00389727 - Simultaneous Integrated Boost (SIB)- IMRT Phase 2
Recruiting NCT02328391 - STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE N/A
Completed NCT00534950 - Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck N/A
Completed NCT00875381 - Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin N/A
Terminated NCT00073450 - Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) Phase 2
Terminated NCT01441128 - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01362127 - Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia Phase 2
Completed NCT00240682 - Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR Phase 2
Terminated NCT02254044 - Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus Phase 1
Active, not recruiting NCT00829192 - Phase II AK Study in Organ Transplant Patients Phase 2
Completed NCT00539630 - TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN Phase 3
Completed NCT00313027 - Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation N/A
Recruiting NCT04564989 - Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
Not yet recruiting NCT06094829 - Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
Recruiting NCT04481256 - TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY N/A
Active, not recruiting NCT02664935 - National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer Phase 2
Terminated NCT02438995 - Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck Phase 1

External Links